01 · Understanding the medicine
What is Psilocybin?
Psilocybin is a naturally occurring compound in some fungi. The body converts it to psilocin, which can alter perception, emotion, memory, time sense, and self-experience. Research is investigating psilocybin-assisted therapy for depression, alcohol use disorder, anxiety and existential distress in serious illness, PTSD, and other conditions; it is not a general-purpose wellness treatment. In supervised trials, the medicine is paired with preparation, psychological support, and follow-up rather than treated as a stand-alone cure. Early findings are encouraging but studies are often small, difficult to blind, short, and conducted with carefully screened adults. A 2023 review of five depression studies (215 participants) found symptom reduction through about five weeks, while comparative evidence has not established superiority to standard care. 1
02 · The science
How it works
Psilocin primarily stimulates serotonin 5-HT2A receptors, especially in cortical networks involved in perception, cognition, and meaning-making. This receptor activity is associated with acute changes in sensory processing and flexible or unusual patterns of brain activity; psychological effects are also shaped by expectations, mood, surroundings, prior experience, and support. Proposed mechanisms include increased emotional learning and a period of heightened plasticity, but these remain active research questions, not settled explanations or guarantees of benefit. 12
03 · Hope, with context
What researchers are exploring
Potential benefit is not a promised outcome. The study population, support, setting, and evidence quality all matter.
Depression symptom relief
Randomized and review evidence suggests that one or more supported sessions may reduce depressive symptoms in the short to medium term for some adults, including people with major depressive disorder. Durability beyond the studied follow-up periods and comparative effectiveness remain uncertain; one trial did not find better symptom reduction than escitalopram plus psychological support. 1
Promising early randomized evidence; small samples, expectancy and blinding challenges, selected participants, and limited long-term data.Alcohol-use outcomes
In a 2022 randomized trial of 93 adults with moderate alcohol use disorder, two psilocybin sessions alongside psychotherapy were associated with fewer heavy-drinking days over 32 weeks than psychotherapy with placebo. The result is encouraging, but most participants correctly guessed their assignment and longer-term persistence is unknown. 1
A single notable trial, not proof of a broadly effective or approved addiction treatment.Distress in serious illness
Small studies in people with advanced or life-threatening cancer suggest possible improvements in anxiety, depression, existential distress, and quality of life when psilocybin is combined with psychotherapy. The evidence is vulnerable to bias and is not readily generalizable to people without serious illness or to unsupervised use. 1
Preliminary pooled evidence from four small studies (117 people); further controlled research is needed.04 · Informed decisions
Safety & medication interactions
Do not start, stop, combine, or taper medicines based on this page. Discuss your complete medication list and health history with your prescriber or pharmacist.
Acute psychological distress
Experiences can be unpredictable and may include fear, panic, confusion, paranoia, disturbing memories, impaired judgment, or hallucinations. Persistent psychosis has been reported. People with schizophrenia, schizoaffective disorder, or severe bipolar disorder should not use psilocybin; screening and a controlled setting matter in research. 1
Cardiovascular and physical effects
Raised heart rate and blood pressure, headache, nausea, dizziness, fatigue, sleep disruption, and other physical effects can occur. These risks warrant particular caution for people with cardiovascular disease or uncontrolled blood pressure; the evidence base often excludes medically vulnerable participants. 12
Medication and substance interactions
Effects may change when psilocybin is combined with psychiatric medicines or other drugs, and the interaction evidence is incomplete. Research is examining SSRIs and other medicines; do not stop, taper, or alter prescribed treatment to pursue psilocybin. Unregulated mushrooms also create risks of misidentification, adulteration, and poisonous look-alikes. 1
Uncertain longer-term and situational harms
Evidence is limited for pregnancy, adolescence, older adults with medical complexity, psychotic-spectrum vulnerability, repeated use, and use outside trained supervision. Very high exposure can be fatal, and a frightening experience can lead to unsafe behavior or lasting distress. 1
Interaction considerations
Interaction studies remain incomplete, including with SSRIs and other psychiatric, migraine, pain, or serotonergic medicines. Alcohol and other psychoactive substances may make effects less predictable and can increase impairment. A qualified healthcare professional should review all medicines, supplements, cardiovascular history, and mental-health history; this entry does not recommend a washout, combination, or dosing plan. 1
Explore the Safety Center05 · The wider story
History, culture & legal context
Indigenous peoples in parts of Mexico and Central America have used psilocybin-containing mushrooms in sacred traditions for thousands of years. That living cultural history deserves respect and must not be presented as clinical validation or separated from community, lineage, consent, and stewardship. Contemporary clinical research is a distinct, regulated practice involving screened participants, trained support, and defined protocols; neither context authorizes appropriation or unsupervised use. 1
Legal context
As of this review date, FDA describes psychedelic drugs as under active development and provides guidance for clinical investigations; that is not approval of psilocybin for depression, addiction, or another condition. In the United States, NCCIH reports that DEA lists psilocybin as Schedule I federally, while some states and the District of Columbia have decriminalized or deprioritized possession and some jurisdictions have specific supervised-service laws. Rules differ by country and can change; verify current local law. 23
06 · Beyond the experience
Preparation & integration
Before
In research or a lawful supervised service, preparation generally includes informed consent, medical and psychiatric screening, discussion of expectations and supports, attention to physical setting, and a plan for urgent care. Preparation is not a guarantee of safety. Do not use this page to select a product, identify mushrooms, calculate an amount, or delay evaluation for a health concern.
After
After an experience, structured follow-up may help a participant reflect on emotions, memories, behavior, and practical goals, while monitoring for worsening mood, mania, psychosis, suicidality, or ongoing perceptual symptoms. Integration is supportive care, not proof that an experience was therapeutic; urgent or persistent symptoms need medical attention.
Questions to bring to your care team
- What condition, symptoms, or goals are being considered, and what established treatments or supports have been discussed with a qualified clinician?
- What mental-health, cardiovascular, pregnancy, medication, substance-use, and emergency-safety factors could change the risk?
- Is the setting lawful and transparent about screening, consent, trained support, follow-up, privacy, cultural respect, and what happens if distress or a medical emergency occurs?
07 · Follow the evidence
Sources & further reading
Read the original work. Publication is not endorsement, and a source check is not independent clinical review.